{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=UCB+Biopharma+S.P.R.L.", "query": { "sponsor": "UCB Biopharma S.P.R.L." }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=UCB+Biopharma+S.P.R.L.&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-08T16:14:55.997Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02804763", "title": "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus (SLE)" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Dapirolizumab pegol (DZP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2016-06-02", "completion_date": "2018-11-19", "has_results": true, "last_update_posted_date": "2021-06-30", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 25, "location_summary": "Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "El Cajon", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02804763" }, { "nct_id": "NCT01529034", "title": "Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "USL261", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 175, "start_date": "2012-07", "completion_date": null, "has_results": true, "last_update_posted_date": "2023-01-20", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01529034" }, { "nct_id": "NCT02161185", "title": "A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "USL261", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": 7, "start_date": "2014-05", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2019-10-10", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 16, "location_summary": "Tucson, Arizona • Fresno, California • Ventura, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Ventura", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Port Charlotte", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02161185" }, { "nct_id": "NCT03707717", "title": "A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 189, "start_date": "2018-10-15", "completion_date": "2019-06-05", "has_results": false, "last_update_posted_date": "2020-06-16", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03707717" }, { "nct_id": "NCT03052751", "title": "Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myasthenia Gravis" ], "interventions": [ { "name": "UCB7665", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2017-05-15", "completion_date": "2018-08-06", "has_results": true, "last_update_posted_date": "2021-08-03", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 6, "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03052751" }, { "nct_id": "NCT01390220", "title": "Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "USL261", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 292, "start_date": "2011-06", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2019-10-10", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01390220" }, { "nct_id": "NCT03531008", "title": "Human Epilepsy Project 2: Resistant Focal Seizures Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Epilepsy", "Brain Diseases", "Central Nervous System Diseases", "Nervous System Diseases", "Biomarkers" ], "interventions": [], "intervention_types": [], "sponsor": "Epilepsy Foundation of America", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 157, "start_date": "2018-05-07", "completion_date": "2022-09-30", "has_results": false, "last_update_posted_date": "2023-09-18", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 10, "location_summary": "San Francisco, California • New Haven, Connecticut • Miami, Florida + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03531008" }, { "nct_id": "NCT03103919", "title": "Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Parkinson´s Disease" ], "interventions": [ { "name": "Kinesia-ONE™", "type": "DEVICE" }, { "name": "Kinesia-360™", "type": "DEVICE" }, { "name": "Rotigotine", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2017-03-16", "completion_date": "2018-01-02", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 8, "location_summary": "Fountain Valley, California • Boca Raton, Florida • Winfield, Illinois + 5 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Winfield", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03103919" }, { "nct_id": "NCT03895385", "title": "A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Bimekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 56, "start_date": "2019-04-02", "completion_date": "2019-10-04", "has_results": false, "last_update_posted_date": "2020-09-17", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03895385" }, { "nct_id": "NCT03357471", "title": "Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate and Severe Active Rheumatoid Arthritis", "Active Psoriatic Arthritis", "Active Ankylosing Spondylitis", "Moderately to Severely Active Crohn's Disease" ], "interventions": [ { "name": "e-Device", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-11-03", "completion_date": "2018-07-02", "has_results": true, "last_update_posted_date": "2019-10-25", "last_synced_at": "2026-10-08T16:14:55.997Z", "location_count": 22, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03357471" } ] }